RAINBOWRainbow Children's Medicare Ltd.
Rainbow Children's Medicare Q2 FY27 Results: Consolidated Net Profit ₹83.89 Crore on Total Income of ₹556 Crore
- Earnings
- Hospitals and healthcare services
Reviewed byRachit TripathiBlacklitt Research
Rainbow Children's Medicare (NSE: RAINBOW) reported consolidated total income of ₹556.15 crore and net profit of ₹83.89 crore for the quarter ended 30 Sep 2026, it said in a filing on 31 Oct 2026. Standalone total income for the quarter was ₹495.08 crore and standalone net profit ₹75.09 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹556.15 crore, up 22.8% YoY and 15.2% QoQ
- Net profit and EPS: ₹83.89 crore, up 10.9% YoY; basic EPS ₹8.10
- Finance costs: ₹22.00 crore, up 16.7% YoY
- Depreciation: ₹44.61 crore, up 24.5% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹495.08 crore, up 18.8% YoY and 17.0% QoQ
- Net profit and EPS: ₹75.09 crore, up 2.6% YoY; basic EPS ₹7.41
- Finance costs: ₹19.91 crore, up 15.0% YoY
- Tax expense: ₹24.77 crore, down 1.8% YoY
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 556.15 | 452.99 | +22.8% | 482.69 | +15.2% | |
| Revenue from operations | 548.02 | 444.80 | +23.2% | 469.99 | +16.6% |
| Other income | 8.13 | 8.20 | -0.8% | 12.71 | -36.1% |
| 83.89 | 75.62 | +10.9% | 62.54 | +34.1% | |
| Profit before tax | 111.50 | 102.37 | +8.9% | 83.95 | +32.8% |
| Finance costs | 22.00 | 18.85 | +16.7% | 21.21 | +3.7% |
| Depreciation | 44.61 | 35.84 | +24.5% | 42.20 | +5.7% |
| Tax expense | 27.61 | 26.75 | +3.2% | 21.41 | +28.9% |
| Net profit margin | 15.08% | 16.69% | -1.61 pp | 12.96% | +2.13 pp |
| EPS, basic (₹) | 8.10 | 7.41 | +9.3% | 5.97 | +35.7% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The company reports a single business segment, rendering medical and healthcare services, operating only in India. Its ESOP 2025 scheme granted 58,260 stock options in the six months to 30 Sep 2026, and employees exercised 2,131 options in the quarter at ₹1,246 each.
On 29 Jul 2026 the company executed transaction documents, including a Shareholders' Agreement, for a new children and women's hospital at Malad, Mumbai, through its wholly owned subsidiary Rainbow Women & Children's Hospital Private Limited, in which it diluted 24% of its stake.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 495.08 | 416.67 | +18.8% | 423.30 | +17.0% | |
| Revenue from operations | 486.99 | 408.50 | +19.2% | 410.55 | +18.6% |
| Other income | 8.09 | 8.17 | -1.0% | 12.76 | -36.6% |
| 75.09 | 73.17 | +2.6% | 52.71 | +42.5% | |
| Profit before tax | 99.87 | 98.40 | +1.5% | 70.54 | +41.6% |
| Finance costs | 19.91 | 17.31 | +15.0% | 19.25 | +3.5% |
| Depreciation | 39.81 | 33.18 | +20.0% | 37.63 | +5.8% |
| Tax expense | 24.77 | 25.23 | -1.8% | 17.84 | +38.9% |
| Net profit margin | 15.17% | 17.56% | -2.39 pp | 12.45% | +2.72 pp |
| EPS, basic (₹) | 7.41 | 7.20 | +2.9% | 5.20 | +42.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 2.6% year on year, against 18.8% growth in total income. Profit before tax rose 1.5% to ₹99.87 crore, and tax expense fell 1.8% to ₹24.77 crore, so the standalone profit growth is much lower than consolidated.
Standalone net profit of ₹75.09 crore is ₹8.80 crore below consolidated net profit of ₹83.89 crore. Standalone other income of ₹8.09 crore is 8.1% of profit before tax.
Depreciation rose 20.0% and finance costs 15.0% year on year. Tax expense of ₹24.77 crore is 24.8% of profit before tax of ₹99.87 crore.
Inference
The filing reports dividend paid of ₹35.55 crore and purchase of treasury shares of ₹42.90 crore in the six months to 30 Sep 2026. The dividend declared for the quarter, if any, is not stated in the filing text.
The company paid ₹18.51 crore upfront and up to ₹19.84 crore in total for the 64% interest in Super Prime Medical Care LLP, with ₹1.33 crore contingent on integration, and recognised goodwill of ₹10.58 crore. The filing does not say how the Malad hospital capacity addition will be timed or funded, nor why the treasury shares were bought.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
